

# Juan Antonio Carbonell-Asins

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6438856/publications.pdf>

Version: 2024-02-01

10  
papers

360  
citations

1464605

7  
h-index

1905433

7  
g-index

10  
all docs

10  
docs citations

10  
times ranked

455  
citing authors

#	ARTICLE	IF	CITATIONS
1	Non-use of information and communication technology as a predictor of frailty in postmenopausal midlife and older women. <i>Maturitas</i> , 2022, 156, 60-64.	1.0	2
2	Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences. <i>Clinical Cancer Research</i> , 2022, 28, 507-517.	3.2	104
3	Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer. <i>Science Advances</i> , 2022, 8, .	4.7	21
4	A prognostic miRNA based signature in early-stage HER2-positive breast cancer patients.. <i>Journal of Clinical Oncology</i> , 2021, 39, e12600-e12600.	0.8	0
5	P606 Adherence to endoscopic surveillance guidelines for advanced lesions and colorectal cancer in Inflammatory Bowel Disease in Spain: a collaborative study of AEG and GETECCU. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S551-S552.	0.6	0
6	Identification of a Two-MicroRNA Signature in Plasma as a Novel Biomarker for Very Early Diagnosis of Breast Cancer. <i>Cancers</i> , 2021, 13, 2848.	1.7	14
7	Molecular profiling of advanced solid tumours. The impact of experimental molecular-matched therapies on cancer patient outcomes in early-phase trials: the MAST study. <i>British Journal of Cancer</i> , 2021, 125, 1261-1269.	2.9	14
8	Detection of postoperative plasma circulating tumour DNA and lack of CDX2 expression as markers of recurrence in patients with localised colon cancer. <i>ESMO Open</i> , 2020, 5, e000847.	2.0	21
9	Circulating tumor DNA to detect minimal residual disease, response to adjuvant therapy, and identify patients at high risk of recurrence in patients with stage I-III CRC.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4009-4009.	0.8	10
10	Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer. <i>Annals of Oncology</i> , 2019, 30, 1804-1812.	0.6	174